Search results
Added:
3 years ago
Mechanical circulatory support (MCS) devices are changing heart failure therapy. A spectrum of devices have become essential to the management of a variety of heart failure scenarios and, in the next few decades, this spectrum will expand and improve thousands of lives each year. The field has grown slowly and at considerable cost over the past 50 years but is now moving rapidly. Devices as small…
View more
Added:
3 years ago
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. The prevalence of AF increases with age;1 one and approximately 2.3 million US adults are currently afflicted with AF, with that number projected to increase to 5.6 million by the year 2050.2
AF typically results in an irregular rhythm with poorly controlled ventricular rate and loss of atrial…
View more
Added:
3 years ago
Atrial fibrillation (AF) is the most common clinically significant arrhythmia, with an overall prevalence of approximately 1 % in the general population.1 An estimated 2.3 million adults in the US have AF, and this number is projected to increase to 5.6 million by 2050.1 The most clinically important complication from AF lies in the risk for cardiac thrombus formation and systemic embolism…
View more
Added:
3 years ago
Atrial fibrillation (AF) is the most common cardiac arrhythmia, becomes more prevalent with age,1 and is associated with an increased long-term risk for stroke, heart failure, and all-cause mortality.2 AF can occur in the absence of underlying heart disease, but is more frequent in connection with mitral valve disease, heart failure, ischemic heart disease, and hypertension.3
Over the past…
View more
Added:
3 years ago
Cardiovascular disease (CVD) is the most common cause of death worldwide.1 With an estimated 7.6 million global deaths due to coronary heart disease in 2005,2 the size of the burden placed on society cannot be understated. Acute myocardial infarction (AMI), the classic ‘heart attack,’ will be the classification given to many of these deaths. In its most life-threatening form, AMI is identified…
View more
Added:
3 years ago
Biomarkers have become central to the management of cardiovascular disease, and their potential clinical applications continue to grow. This article reviews galectin-3 (Gal-3), a novel biomarker of fibrosis and remodeling, and its clinical application in heart failure (HF).
Case Studies
Case Study One
A 63-year-old African-American female presents to the emergency department with acute dyspnea…
View more
Added:
3 years ago
Several cardiac biomarkers may aid in the diagnostic and prognostic evaluation of acute and chronic heart failure. In this article we discuss more novel and emerging applications of such established cardiac biomarkers in heart failure and review emerging data for several other promising markers.
Novel Applications of Established Cardiac Biomarkers—Natriuretic Peptides
B-type natriuretic peptide…
View more
Added:
7 months ago
Added:
2 years ago
Added:
2 years ago
